-
Zafgen Shares Surge On Positive Phase 3 Trial
Monday, April 4, 2016 - 8:06am | 329Read More...Shares of Zafgen Inc (NASDAQ: ZFGN) gained more than 14 percent early Monday morning after the company announced positive data from a Phase 3 trial evaluating the safety and efficacy of beloranib. The study evaluated the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with...
-
Thromboembolic Risks Linger For Zafgen's Beloranib, Says SunTrust
Friday, February 19, 2016 - 5:05pm | 262Read More...SunTrust said it hasn't changed its benefit-risk profile for Zafgen Inc (NASDAQ: ZFGN)'s beloranib, citing that thromboembolic risks linger on the obesity drug that showed statistically and clinically significant improvements in body weight and glycemic control in a mid-stage trial. Related Link:...
-
Zafgen Doubles: What Do The Experts Think?
Thursday, January 21, 2016 - 12:51pm | 388Read More...Recently, analysts from FBR & Co. and RBC Capital Markets gave their take on Zafgen Inc (NASDAQ: ZFGN) after the company's stock price soared on news that their beloranib drug had positive Phase III data. RBC Capital Markets upgraded Zafgen from Sector Perform to Outperform and raised their...
-
Why Zafgen Is Trading Higher By 40%
Wednesday, January 20, 2016 - 9:45am | 320Read More...Shares of Zafgen Inc (NASDAQ: ZFGN), a biopharmaceutical company that develops therapies for patients affected by obesity and complex metabolic disorders, were trading higher by nearly 40 percent at $7.80 early Wednesday morning. Zafgen announced after Tuesday's market positive efficacy...
-
Zafgen Controversy Means Stock Is Worth $25 Now, Notes SunTrust
Monday, October 19, 2015 - 2:40pm | 304Read More...Zafgen Inc (NASDAQ: ZFGN) shares have plunged 67 percent since October 13, after trading above $40 in 2015. SunTrust Robinson Humphrey’s Edward Nash maintained a Buy rating on the company, while reducing the price target from $47 to $25. The partial clinical hold of a trial for beloranib has...
-
RBC Spoke With Zafgen Management After The Beloranib Patient Death; Here Are The Takeaways
Wednesday, October 14, 2015 - 3:32pm | 491Read More...Zafgen Inc (NASDAQ: ZFGN) said on Wednesday that a patient has died during a late-stage trial conducted by the company for its Beloranib drug. The company commented that there is still a 33 percent chance that the death was on the placebo arm. Analysts at RBC Capital Markets spoke with management...
